General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Genetics may determine who responds well to Wegovy: report (NYSE:NVO) | news.google.com • |
Hims & Hers surges on cheap compounded versions of Novo Nordisk's semaglutide | news.google.com • |
Novo Nordisk weight loss drugs still showing upside risk - analyst | proactiveinvestors.co.uk • |
Novo Nordisk weight loss drugs still showing upside risk - analyst | proactiveinvestors.co.uk • |
SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued? (NYSE:LLY) | news.google.com • |
SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued? (NYSE:LLY) | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-02 | 2024-03 | 0.77 | 0.83 | 0.06 | 7.79% |
2024-01-31 | 2023-12 | 0.66 | 0.71 | 0.05 | 7.58% |
2023-11-02 | 2023-09 | 0.69 | 0.73 | 0.04 | 5.80% |
2023-08-10 | 2023-06 | 0.67 | 0.63 | -0.04 | -5.97% |
2023-05-04 | 2023-03 | 0.64 | 0.64 | N/A | N/A |
2023-02-01 | 2022-12 | 0.41 | 0.42 | 0.01 | 2.44% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-01 | Argus Research | Upgrade | Buy | |
2023-03-27 | BTIG | Upgrade | Buy | |
2022-12-11 | TD Cowen | Upgrade | Outperform | |
2022-06-27 | UBS | Downgrade | Neutral | Sell |
2022-06-06 | JP Morgan | Upgrade | Neutral | Overweight |
2022-05-30 | Guggenheim | Upgrade | Neutral | Buy |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Jennison Associates LLC | 23.38M | 1.89B | 0.68% |
2023-06-29 | Renaissance Technologies, LLC | 18.74M | 1.52B | 0.55% |
2023-06-29 | Fisher Asset Management, LLC | 15.24M | 1.23B | 0.44% |
2023-06-29 | Bank of America Corporation | 12.46M | 1.01B | 0.36% |
2023-06-29 | FMR, LLC | 10.85M | 877.59M | 0.32% |
2023-06-29 | Sarofim, Fayez & Co | 10.24M | 828.52M | 0.30% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-07-30 | Harbor Capital Appreciation Fund | 5.93M | 477.51M | 0.17% |
2023-09-29 | Washington Mutual Investors Fund | 3.44M | 313.26M | 0.10% |
2023-05-30 | Vanguard U.S. Growth Fund | 2.71M | 217.51M | 0.08% |
2023-06-29 | Loomis Sayles Growth Fund | 2.38M | 192.32M | 0.07% |
2023-05-30 | Amana Mutual Funds Trust-Growth Fund | 2.00M | 160.72M | 0.06% |
2023-06-29 | College Retirement Equities Fund-Growth Account | 2.13M | 172.68M | 0.06% |
Dividend | Date |
---|---|
0.13476 | 2024-03-22 |
0.129 | 2023-08-18 |
0.1724 | 2023-03-24 |
0.0804 | 2022-08-12 |
0.1531 | 2022-03-25 |
0.0876 | 2021-08-16 |
Split | Date |
---|---|
2 : 1 | 2023-09-20 |
5 : 1 | 2014-01-09 |
2 : 1 | 2007-12-17 |
2.5 : 1 | 2001-04-11 |
4 : 1 | 1994-04-18 |
Pump and dump
Timber !!!
$99.00
This should be up on the news of coverage for $NVO Wegovy
This needs to get on up. $NVO got tha goods.
Not selling! Please go down so I can add
Earnings in May
Holds up strong during a down market day. Amazing and will rocket higher. Inflation or not, people need this drug and will continue to need it for years.
Which is more important, Novo which is making life saving drugs currently at $131 a share, or Apple which makes electronics currently priced at $171 a share. These two stocks alone should have the opposite share prices. I predict in the near future this will happen.
You can see people buying the dip
Added more shares to this monster!
This stock is an absolute monster in the making.
Please keep going down so I can add more!
$IBRX revenue may double after thay get in to China market. That's crazy.
This is the next Nvidia
Why the pop this morning?
If they make “obesity” an official disease then insurance will have to cover everyone. 🤯
$NVO Total Overreaction. Buying this here